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D E NOVO diabetes mellitus is encountered in approx-imately 10% of patients treated with either Tacroli-
mus (FK506) or cyclosporin (CSA) within the first year 
posttransplantation.1.2 This outcome is largely attributed to 
the direct inhibitory effects of these primary immunosup-
pressants on pancreatic islet cell function and on their 
ability to release insulin. While this altered glucoregulatory 
function can be reversed in the majority of patients by dose 
reduction, it nevertheless has an adverse influence on 
long-term patient and graft survival. The latter finding has 
fomented interest in the discovery of novel immunosup-
pressive agents, which in addition to preventing rejection, 
would also be innocuous to f3 cells, thus allowing wide-
spread clinical use of islet cell transplantation (Tx) for the 
treatment of insulin-dependent type I diabetes mellitus 
(100M). Leflunomide (LEF) is a powerful immunosup-
pressive agent, which when used in rats, prevented kidney 
and skin allograft rejection.3 Interestingly, when used in 
combination with subtherapeutic doses of CyA, it also 
enhanced islet allograft survival in preclinical models of 
diabetes.4 However, the efficacy of LEF used in combina-
tion with sub therapeutic, nondiabetogenic doses of FK506 
to prevent islet cell rejection, has as yet not been ascer-
tained; this study was therefore designed to address this 
latter issue. 
MATERIALS AND METHODS 
Animals and Islet Cell Transplantation 
Male MHC-disparate ACI (RTla) and LEW (RTl') rats were used 
as donors and recipients respectively of islet cell Tx. Recipients 
were rendered hyperglycemic by streptozotocin administration (60 
mg/kg; IV; day -4) followed by implantation of isolated islets 
(approximately.1.3 x 103 per animal) under the left kidney capsule; 
their blood glucose levels and body weight were serially measured 
thereafter. Based on the regimen used. the animals were divided 
into ninc groups (Table 1). 
RESULTS AND DISCUSSION 
Untreated recipients (Group I) rejected their grafts within 
10 days post-Tx, whereas; modest prolongation was 
achieved in animals treated with two different doses of LEF 
alone (Table 1; Groups II and III). Interestingly, when used 
alone. subtherapeutic doses of FK506 also resulted in 
moderate prolongation of islet allograft survival with main-
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Table 1. Graft Survival Following Islet Cell Transplantation 
Across ACI .... LEW Rat Strain Combination 
Treatment (mg/kg/d)2 
Graft Survival (days) 
Groups' LEF3 (gavage) FK506 (1M) (mean!: SO) 
9=1 
II 0.2 19 = 2 
III 0.5 21 = 4 
IV 5 30 = 3 
V 10 30 = 2 
VI 0.2 5 41 = 3 
VII 0.2 10 39 = 6 
VIII 0.5 5 39 = 3 
IX 0.5 10 40 = 5 
'n = 4/group. 
2Administered daily from day 0-14 post-Tx. 
30btained as a generous gift from CINKATE Corporation. Oak Park. IL. 
tenance of euglycemia for up to 30 days post-Tx (Table 1). 
However, islet allograft survival was further augmented 
when both LEF and FK506 were administered simulta-
neously (Table 1; Groups VI to IX). It is noteworthy that 
allograft survival was comparable in animals treated con-
temporaneously with either low or high doses of LEF 
(Table 1; Groups VI and VII) and FK506 (Table 1; Groups 
VIII and IX), suggesting that this drug combination could 
be used at relatively lower doses to achieve the desired 
outcome. In addition to being relatively innocuous to 
transplanted islets. LEF and FK506, when used either alone 
or in combination. had little or no effect on recipient's body 
weight. which continued to increase during the course of 
this analysis. From these observations. we conclude that 
LEE when used alone. prolongs islet allograft survival, an 
effect further potentiated by its combined use with sub-
therapeutic nondiabetogenic doses of FK506. It is there-
fore. rational to suggest that this drug combination could 
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PROLONGED SURVIVAL OF ISLET ALLOGRAFTS 
serve as an ideal immunosuppressive regimen for successful 
clinical islet cell Tx. 
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